MFG
LAB icon

Merit Financial Group’s Standard BioTools LAB Stock Holding History

Merit Financial Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12K Buy
14,544
+3,031
+26% +$2.86K ﹤0.01% 2347
2026
Q1 		$10.6K Buy
+11,513
New +$13.9K ﹤0.01% 2106

Other funds holding LAB

MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Merit Financial Group's LAB Position: Q2 2026 in Review

Merit Financial Group increased its Standard BioTools (LAB) stake by 26% in Q2 2026, buying an estimated $2.86K and bringing the position to 14,544 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #2347.

Merit Financial Group first reported a position in LAB in Q1 2026 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Merit Financial Group held 14,544 shares of Standard BioTools worth $12K as of Q2 2026.
  • Merit Financial Group bought 3,031 Standard BioTools shares in Q2 2026, an estimated $2.86K.
  • Standard BioTools made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #2347 holding.
  • Merit Financial Group first reported a position in Standard BioTools in Q1 2026 and has held it in 2 quarters since.
  • 7 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.